The content on this site is intended for healthcare professionals only
Cancer patient symptom and physical function reporting by caregivers used as pre...
Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, ...
21 Jun 2022
War in Ukraine: Global cancer aid to support refugees
Dr Horia Vulpe , Dr Ruslan Baltaga
21 Jun 2022
War in Ukraine: The International Brain Tumour Alliance's response to aiding ref...
Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance
21 Jun 2022
ASCO and WHO to collaborate on quality indicators for cancer facilities
Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland
14 Jun 2022
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG1...
Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA
10 Jun 2022
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
10 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
9 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
6 Jun 2022
Comment: Dabrafenib plus trametinib significantly increases overall response rat...
Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA
6 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
6 Jun 2022
OncoAlert and ecancer weekly round up for October 18th - October 23rd, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
26 Oct 2021
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and br...
Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA
6 Oct 2021